AVITA Medical (RCEL) Status update summary

Business outlook and strategic focus

• Emphasis on disciplined execution, predictability, and progressive revenue growth for 2026, with a focus on removing distractions and headwinds, particularly around financial covenants.

• Revenue guidance for 2026 set at $80–$85 million, reflecting a bottoms-up approach and confidence in forecasting accuracy, representing 12–19% growth.

• Sales force restructured to focus on 200 key accounts, including burn and trauma centers, with cost reductions and strategic geographic deployment.

• Three-product platform (RECELL, RECELL GO, Cohealyx, PermeaDerm) positioned for expanded utilization and account penetration, addressing distinct acute wound care needs.

• International expansion underway, with trained distributors in Japan, Australia, EU, and UK, and early-stage efforts in Europe.

Financial performance and guidance

• Achieved $71.6 million in revenue for the year, representing 11% growth; Q4 revenue was $17.6 million, showing stability.

• Gross profit margin for the year was 82.1%, impacted by inventory reserves and product mix; expected to improve to 83–85% as RECELL outpaces other products.

• Operating expenses normalized to $23–$24 million per quarter after significant cost reductions, including $10 million annual savings; FY 2025 net loss improved to $(48.6)M from $(61.8)M in FY 2024.

• Cash usage reduced each quarter, with a path to cash flow breakeven anticipated as revenue grows; cash position supported by a $13.8M equity raise and a new $60M debt facility.

• New $60 million credit facility with Perceptive Advisors reset revenue covenants, reducing financial distractions and providing headroom for growth.

Product adoption and market strategy

• RECELL expansion focuses on increasing utilization within existing accounts and physicians, leveraging strong relationships in 90% of target accounts.

• Cohealyx and PermeaDerm adoption progressing through value analysis committees (VACs), with about 55 accounts in process and a dozen approvals expected per quarter.

• Portfolio enables rapid wound stabilization, healing acceleration, and optimized closure, with average selling prices ranging from ~$7,680 to ~$67,360 depending on wound severity.

• Focused strategy targets ~200 high-volume U.S. burn and trauma centers, with current market penetration at ~5% of a $1.3B addressable market.

• Focus on consultative selling and multi-product use within the same patient and account to drive per-patient revenue.